Haleon (LON:HLN) Insider Brian McNamara Sells 704,974 Shares

Haleon plc (LON:HLN) insider Brian McNamara sold 704,974 shares of the business’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of GBX 368, for a total value of £2,594,304.32.

Brian McNamara also recently made the following trade(s):

• On Monday, March 23rd, Brian McNamara sold 63,012 shares of Haleon stock. The shares were sold at an average price of GBX 368, for a total transaction of £231,884.16.

Haleon Stock Down 2.3%

LON:HLN traded down GBX 8.30 during trading hours on Tuesday, hitting GBX 357.30. The stock had a trading volume of 142,630,016 shares, compared to its average volume of 38,006,121. The business has a 50 day simple moving average of GBX 385.90 and a two-hundred day simple moving average of GBX 367.45. Haleon plc has a 1-year low of GBX 325.10 and a 1-year high of GBX 419.50. The company has a current ratio of 0.92, a quick ratio of 0.93 and a debt-to-equity ratio of 52.26. The company has a market cap of £31.82 billion, a PE ratio of 19.31, a price-to-earnings-growth ratio of 1.49 and a beta of 0.25.

Haleon (LON:HLN) last announced its earnings results on Thursday, February 26th. The company reported GBX 18.60 earnings per share (EPS) for the quarter. Haleon had a return on equity of 9.44% and a net margin of 13.81%. Analysts predict that Haleon plc will post 19.5033282 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. JPMorgan Chase & Co. boosted their target price on Haleon from GBX 315 to GBX 335 and gave the stock an “underweight” rating in a report on Wednesday, November 26th. Deutsche Bank Aktiengesellschaft dropped their price objective on Haleon from GBX 340 to GBX 335 and set a “buy” rating on the stock in a research note on Thursday, January 22nd. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 450 target price on shares of Haleon in a research note on Wednesday, January 21st. Finally, Berenberg Bank lifted their target price on Haleon from GBX 510 to GBX 512 and gave the stock a “buy” rating in a report on Thursday, March 19th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of GBX 407.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.